Clinical Validation at BELNUC 2025

At the 23rd BELNUC Symposium, Nuclivision shared new clinical evidence supporting Nuclarity’s role in PET image enhancement.

Maarten Larmuseau, cofounder of Nuclivision, presented results from a multicenter, multi-tracer study showing how Nuclarity improves low-count PET images — enabling shorter scan times and lower doses. The talk, titled "Low-count whole-body PET with deep learning in a multicenter, multi-tracer and externally validated study", underscored the robustness of the algorithm across clinical sites and tracers.

A poster on "Generalizing Deep Learning Denoising for Novel PET Radiotracers to Improve Image Quality" further demonstrated Nuclarity’s performance on tracers beyond 18F-FDG.

We also welcomed discussions at our booth with clinicians and researchers interested in testing or clinical integration of Nuclarity into their clinical workflows.

‍